Furthermore, administration of mesenchymal stromal cells (MSCs) even at 7 days after stroke substantially increased NG2 positive OPCs in the SVZ and MBP positive oligodendrocytes in the peri-infarct striatum and corpus callosum 4 months after stroke (Li et al., 2005). The gene discussed is CSPG4; the disease is stroke disorder.